Potent, selective ACSS2 inhibitory compounds with potential in CNS diseases

具有中枢神经系统疾病潜力的强效选择性ACSS2抑制化合物

PHILADELPHIA, Jan. 16, 2024 /PRNewswire/ -- EpiVario Inc., a biotech company pioneering neuroepigenetics to treat addiction disorders, today announced that it has entered into an asset purchase agreement with Metabomed LTD ('Metabomed') to acquire Metabomed's small molecule acetyl co-A synthetase-2 inhibitor ('ACSS2i') portfolio.  The acquired assets and associated intellectual property encompass novel, potent and selective 'next generation' ACSS2i, as well as other ACSS2i compounds that had previously been developed by Metabomed for treatment of advanced cancers, including the clinical candidate known as MTB9655.  The transaction provides EpiVario with novel, potent and selective small molecule ACSS2i compounds that may have potential for treatment of addiction disorders, in which ACSS2 is believed to play an important role.

费城，2024年1月16日/PRNewswire/--EpiVario Inc.，一家开创神经表观遗传学治疗成瘾疾病的生物技术公司，今天宣布，它已经与Metabomed LTD（“Metabomed”）签订了资产购买协议，以收购Metabomed的小分子乙酰辅酶a合成酶-2抑制剂（“ACSS2i”）投资组合。收购的资产和相关知识产权包括新颖，有效和选择性的“下一代”ACSS2i，以及之前由Metabomed开发用于治疗晚期癌症的其他ACSS2i化合物，包括临床候选物MTB9655。该交易为EpiVario提供了新颖，强效和选择性的小分子ACSS2i化合物可能具有治疗成瘾的潜力，其中ACSS2被认为起着重要作用。

.

.

'The acquisition of Metabomed's ACSS2i portfolio provides EpiVario with a proprietary, next generation portfolio of novel, potent and selective small molecule ACSS2 inhibitors,' said Thomas Kim, President and Chief Executive Officer of EpiVario. 'We are enthusiastic to have executed this deal with Metabomed, which provides EpiVario an advanced foundation to build onto Metabomed's expertise around ACSS2, providing the potential to rapidly identify an ACSS2i lead compound.   The deal provides EpiVario a rich array of novel, patent-protected compounds that may accelerate EpiVario's development program directed to addiction disorders, including opioid, cocaine and alcohol addiction, and also PTSD.'.

EpiVario总裁兼首席执行官托马斯·金（ThomasKim）说，收购Metabomed的ACSS2i投资组合为EpiVario提供了专有的下一代新型、有效和选择性小分子ACSS2抑制剂投资组合我们很高兴与Metabomed达成这项交易，这为EpiVario提供了一个先进的基础，以巩固Metabomed在ACSS2方面的专业知识，从而有可能快速识别ACSS2i先导化合物。该协议为EpiVario提供了一系列受专利保护的新型化合物，这些化合物可能会加速EpiVario针对成瘾性疾病（包括阿片类药物，可卡因和酒精成瘾以及创伤后应激障碍）的开发计划。”。

ABOUT EPIVARIO INC.

关于EPIVARIO INC。

EpiVario is pioneering novel epigenetic therapeutics for the treatment of neuropsychiatric disorders.  Spun out of the Epigenetics Institute of The University of Pennsylvania, the company is developing pharmacotherapeutics that target a newly discovered epigenetic process in long term memory formation.  By targeting this activity to modulate stress and drug-related memories, EpiVario is establishing a novel, differentiated, and promising approach to address substance use disorders and PTSD..

EpiVario是治疗神经精神疾病的新型表观遗传疗法的先驱。该公司由宾夕法尼亚大学表观遗传学研究所（Epigenetics Institute of the University of Pennsylvania）推出，目前正在开发针对长期记忆形成中新发现的表观遗传过程的药物治疗剂。通过针对这种活动来调节压力和与药物相关的记忆，EpiVario正在建立一种新的，有区别的，有前途的方法来解决物质使用障碍和创伤后应激障碍。。

For further information, please visit https://www.epivario.com

For further information, please visithttps://www.epivario.com

CONTACT:  [email protected]

联系人：[受电子邮件保护]

Follow EpiVario Inc. on Twitter at @EpiVario, and on LinkedIn at https:///www.linkedin.com/company/epivario/

关注EpiVario Inc.在Twitter上的@EpiVario，以及LinkedIn上的https:///www.linkedin.com/company/epivario/

SOURCE EpiVario Inc.

Source Epivario公司。